Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Research & Development (2016 - 2025)

Historic Research & Development for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to $8.1 million.

  • Theravance Biopharma's Research & Development fell 1247.3% to $8.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.5 million, marking a year-over-year increase of 822.95%. This contributed to the annual value of $37.6 million for FY2024, which is 733.12% down from last year.
  • According to the latest figures from Q3 2025, Theravance Biopharma's Research & Development is $8.1 million, which was down 1247.3% from $10.5 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Research & Development registered a high of $67.6 million during Q1 2021, and its lowest value of $8.1 million during Q3 2025.
  • In the last 5 years, Theravance Biopharma's Research & Development had a median value of $10.5 million in 2025 and averaged $19.2 million.
  • Its Research & Development has fluctuated over the past 5 years, first crashed by 7744.12% in 2022, then skyrocketed by 2769.85% in 2025.
  • Quarter analysis of 5 years shows Theravance Biopharma's Research & Development stood at $31.2 million in 2021, then plummeted by 50.85% to $15.3 million in 2022, then crashed by 45.84% to $8.3 million in 2023, then grew by 13.71% to $9.5 million in 2024, then fell by 14.19% to $8.1 million in 2025.
  • Its Research & Development stands at $8.1 million for Q3 2025, versus $10.5 million for Q2 2025 and $11.5 million for Q1 2025.